Succinate is a four-carbon dicarboxylic acid (C₄H₆O₄) that serves as both a mitochondrial intermediate in the tricarboxylic acid (TCA) cycle and an extracellular signaling molecule. Under hypoxic or inflammatory conditions, succinate accumulates and stabilizes Hypoxia-Inducible Factor (HIF)-1α by inhibiting prolyl hydroxylase domain (PHD) enzymes, creating a "pseudohypoxic" state that drives pro-inflammatory gene expression. Extracellularly, succinate activates SUCNR1 (GPR91), a G-protein coupled receptor that amplifies inflammatory responses in leukocytes, particularly M1 macrophages.
Imagine a factory assembly line where raw materials normally flow smoothly from station to station. Succinate is like a pallet of materials that usually gets passed quickly from Complex I to Complex II (the "succinate processing station") and converted into the next product, fumarate. But when the oxygen supply is cut off—like when the factory's ventilation fails—this pallet starts piling up at the station. The stacked pallets block the normal quality control inspector (PHD enzymes) from entering the management office to file a "shut down production" report (degrading HIF-1α). With the inspector blocked, the factory manager (HIF-1α) stays at their desk and starts issuing emergency orders: "Ramp up glycolysis! Build more blood vessels! Release inflammatory signals!" Meanwhile, some of those stacked pallets spill out of the factory into the street (extracellular space), where they act as alarm signals to passing emergency response vehicles (immune cells via SUCNR1 receptor), telling them "There's a crisis here—send reinforcements!" The factory has now switched from normal production mode to emergency crisis mode, all because succinate couldn't be cleared fast enough.
Intracellular TCA Cycle Role:
Under aerobic conditions, succinate is generated from succinyl-CoA by succinyl-CoA synthetase in the TCA cycle, then oxidized to fumarate by succinate dehydrogenase (SDH, Complex II) → electrons transferred to coenzyme Q → continued through electron transport chain.
Succinate Accumulation Pathways:
graph TD
A["Hypoxia/<br/>Inflammation"] --> B["Inhibition of<br/>Complex I/III/IV"]
B --> C["Reverse Electron<br/>Transport at Complex II"]
C --> D[Succinate Accumulation]
A --> E[Glutamine Oxidation]
E --> F["α-ketoglutarate → Succinate<br/>via reductive TCA"]
F --> D
A --> G[GABA Shunt Activation]
G --> H["Succinate Semialdehyde<br/>→ Succinate"]
H --> D
D --> I[Inhibit PHD1/2/3 Enzymes]
I --> J["Block HIF-1α Hydroxylation"]
J --> K["HIF-1α Stabilization<br/>even in normoxia"]
K --> L["HIF Target Genes:<br/>VEGF, GLUT1, IL-1β,<br/>Glycolytic Enzymes"]
D --> M["Export via<br/>MCT1/MCT4/INDY"]
M --> N[Extracellular Succinate]
N --> O["SUCNR1/GPR91<br/>Activation"]
O --> P["Gαi/Gαq Signaling"]
P --> Q["↑ cAMP, ↑ Ca²⁺"]
Q --> R["Enhanced IL-1β,<br/>TNF-α, ROS Production"]
HIF-1α Stabilization Cascade:
- Normal conditions: PHD1/2/3 enzymes (requiring O₂, Fe²⁺, and 2-Oxoglutarate) → hydroxylate HIF-1α at Pro402/Pro564 → recognized by von Hippel-Lindau (VHL) E3 ubiquitin ligase → proteasomal degradation (t½ <5 minutes)
- Succinate accumulation (>10-fold above baseline ~5 mM → >50 mM intracellularly): succinate competes with 2-Oxoglutarate (α-ketoglutarate) at PHD active site (competitive inhibition, Km ~100 μM for 2-OG, but succinate accumulates to mM levels) → PHD activity blocked → HIF-1α escapes hydroxylation → translocates to nucleus → dimerizes with HIF-1β/ARNT → binds hypoxia response elements (HREs: 5'-RCGTG-3') → transcriptional activation
SUCNR1 Signaling:
Extracellular succinate (released via monocarboxylate transporters MCT1/MCT4 or cellular damage) → binds SUCNR1 (GPR91, expressed on dendritic cells, M1 macrophages, retinal ganglion cells, kidney epithelium) → coupled to Gαi (inhibits adenylyl cyclase) and Gαq (activates phospholipase C) → ↑ intracellular Ca²⁺, ↑ ERK1/2, ↑ AKT phosphorylation → enhanced NF-κB activation → ↑ IL-1β, TNF-α, IL-6, Reactive Oxygen Species (ROS) production via NLRP3 inflammasome priming.
Metabolic Rewiring in Inflammation:
LPS activation of macrophages → breaks TCA cycle at two points:
- Inhibition of isocitrate dehydrogenase (IDH) → citrate accumulation → exported for fatty acid synthesis
- Glutamine oxidation via reductive carboxylation: glutamine → glutamate → α-ketoglutarate → (running TCA backwards) → succinate accumulation
Result: succinate rises 10-100-fold within 4-6 hours of LPS stimulation in M1 macrophages.
Quantitative Thresholds:
- Baseline intracellular succinate: ~0.2-0.5 mM
- Hypoxic accumulation: 5-20 mM (10-40x increase)
- LPS-activated macrophages: peak at 6-8 hours, sustained for 12-24 hours
- Extracellular succinate in inflammatory sites: 100-800 μM (10-100x plasma levels)
- Plasma succinate (healthy): 1-10 μM; sepsis: up to 100 μM
Metabolic-Immune Interface:
Succinate represents a critical node where metabolic dysfunction directly translates into immune activation—a cornerstone of the Selfish Immune System concept. In cPNI practice, elevated succinate indicates a shift from oxidative metabolism to glycolytic/inflammatory metabolism, linking Metabolic dysfunction, chronic low-grade inflammation, and tissue hypoxia.
Clinical Conditions:
-
Chronic inflammation: Persistently elevated succinate in Obesity, Type 2 Diabetes, Metabolic syndrome—macrophages shift to M1 phenotype, maintaining metaflammation. Intervention: restore mitochondrial function via Intermittent fasting, Exercise, mitochondrial nutrients (CoQ10, Alpha-lipoic acid).
-
Rheumatoid arthritis, Inflammatory bowel disease: Synovial/intestinal succinate levels correlate with disease activity. Synovial fluid succinate: 200-400 μM (vs. <50 μM in healthy joints). SUCNR1 antagonism shows promise in animal models.
-
Ischemia-reperfusion injury: Succinate accumulates during ischemia, then drives ROS burst upon reperfusion via reverse electron transport at Complex II → oxidative damage. Perioperative interventions: malonate (SDH inhibitor) or dimethyl malonate reduce injury in cardiac surgery trials.
-
Cancer: Mutations in SDH genes (succinate dehydrogenase subunits SDHA/B/C/D) → hereditary paraganglioma/pheochromocytoma syndromes → "oncometabolite" accumulation → constitutive HIF activation → Warburg Effect phenotype, angiogenesis. Known as "Pseudohypoxia" cancers.
-
Sepsis and ARDS: Plasma succinate >50 μM predicts mortality in sepsis (AUC 0.76 in validation cohorts). Represents systemic metabolic failure and immune hyperactivation.
Evolutionary Mismatch Context:
The succinate-HIF axis evolved as a short-term emergency response to hypoxia (e.g., high altitude, acute infection). Chronic activation in Metabolic syndrome represents an Evolutionary mismatch—the body interprets chronic metabolic stress (hyperglycemia, free fatty acids, Chronic stress) as perpetual hypoxia, driving maladaptive chronic inflammation. The Thrifty genotype may have selected for robust HIF responses (survival advantage in infection/starvation), now maladaptive in caloric excess.
Intervention Implications:
-
Restore aerobic metabolism:
-
Target HIF pathway:
- Metformin (↓ Complex I, ↓ succinate via altered redox state)
- Dimethyl fumarate (competes with succinate at PHD enzymes, used in MS)
- Vitamin C (co-factor for PHD enzymes, ↑ HIF degradation at doses >1g/day)
-
Anti-inflammatory diet:
-
Address hypoxia:
- Sleep apnea treatment (eliminate intermittent hypoxia cycles)
- Breathing exercises (improve tissue oxygenation, Wim Hof method)
Biomarker Use:
- Urinary succinate: non-invasive marker for mitochondrial dysfunction (↑ in Chronic fatigue syndrome, Fibromyalgia)
- Serum succinate: emerging biomarker for sepsis severity, Diabetes complications
- Synovial/tissue succinate: direct measure of local metabolic-inflammatory state
Exam Relevance:
Succinate exemplifies the "metabolite as signal" paradigm central to Module 5. Students must understand: (1) how metabolic context determines whether succinate is just a TCA intermediate or becomes a pro-inflammatory signal, (2) the dual mechanism (intracellular HIF stabilization + extracellular SUCNR1 activation), and (3) clinical application—identifying patients with metabolic-inflammatory coupling and intervening at the metabolic level to resolve inflammation.
- Four-carbon dicarboxylic acid (C₄H₆O₄), normal TCA cycle intermediate oxidized by Complex II (succinate dehydrogenase)
- Accumulates 10-100-fold in hypoxia and LPS-activated M1 macrophages (baseline ~0.5 mM → 5-50 mM intracellularly)
- Competitively inhibits PHD1/2/3 enzymes (Km for 2-Oxoglutarate ~100 μM; succinate reaches mM levels), stabilizing HIF-1α in normoxia ("Pseudohypoxia")
- Signals via SUCNR1/GPR91 receptor (Gαi/Gαq-coupled) on dendritic cells, M1 macrophages, kidney epithelium → ↑ IL-1β, TNF-α, ROS
- Peak accumulation in LPS-activated macrophages: 6-8 hours post-stimulation, sustained 12-24 hours
- Plasma levels: healthy 1-10 μM; sepsis >50 μM (mortality predictor); synovial fluid in Rheumatoid arthritis 200-400 μM
- SDH mutations (SDHA/B/C/D) → hereditary paraganglioma/pheochromocytoma → "oncometabolite" driving HIF-dependent tumorigenesis
- Drives reverse electron transport at Complex II during ischemia-reperfusion → ROS burst → oxidative damage
- Urinary succinate elevated in Chronic fatigue syndrome, Fibromyalgia, mitochondrial dysfunction
- Intervention targets: Metformin, Vitamin C (PHD cofactor), Dimethyl fumarate (competitive inhibitor), Ketogenic diet, High-intensity interval training
- Hypoxia-Inducible Factor — succinate stabilizes HIF-1α by inhibiting PHD enzymes, creating pseudohypoxic state even in normal oxygen
- 2-Oxoglutarate — succinate competitively inhibits α-ketoglutarate-dependent PHD enzymes; imbalance between these metabolites determines HIF stability
- TCA cycle — succinate is Complex II substrate; metabolic rewiring in Inflammation breaks cycle and accumulates succinate via glutamine oxidation
- M1 macrophages — succinate accumulation drives M1 polarization and pro-inflammatory phenotype via HIF-1α and SUCNR1 signaling
- IL-1β — succinate-stabilized HIF-1α transcriptionally activates IL-1β; SUCNR1 primes NLRP3 inflammasome for IL-1β processing
- LPS — lipopolysaccharide triggers metabolic rewiring in macrophages causing 10-100-fold succinate accumulation within 4-6 hours
- Warburg Effect — succinate accumulation contributes to aerobic glycolysis in cancer and activated immune cells; SDH mutations cause hereditary cancers
- Pseudohypoxia — succinate-mediated HIF stabilization without true hypoxia; occurs in SDH-mutant cancers and metabolic disease
- Reactive Oxygen Species — succinate drives ROS production via reverse electron transport at Complex II and SUCNR1-mediated NADPH oxidase activation
- Metformin — inhibits Complex I, alters mitochondrial redox state to reduce succinate accumulation; mechanism for anti-inflammatory effects
- Ketogenic diet — shifts metabolism away from glycolysis, reduces succinate accumulation, increases Beta-hydroxybutyrate which inhibits NLRP3 inflammasome
- Mitochondrial dysfunction — impaired SDH activity or hypoxia causes succinate buildup; urinary succinate is biomarker for mitochondrial disease
- Ischemia-reperfusion injury — succinate accumulates during ischemia, drives massive ROS burst upon oxygen restoration via Complex II reverse electron transport
- Chronic low-grade inflammation — persistently elevated succinate in Obesity and Type 2 Diabetes maintains inflammatory macrophage activation
- Sepsis — plasma succinate >50 μM predicts mortality; represents systemic metabolic failure and immune hyperactivation
- Rheumatoid arthritis — synovial fluid succinate 200-400 μM correlates with disease activity; SUCNR1 expressed on synovial macrophages
- Inflammatory bowel disease — intestinal succinate drives mucosal inflammation via SUCNR1 on dendritic cells and epithelium
- VEGF — HIF-1α target gene; succinate accumulation drives angiogenesis in tumors and chronic wounds via VEGF upregulation
- GLUT1 — glucose transporter upregulated by succinate-stabilized HIF-1α, facilitating Warburg Effect and glycolytic metabolism
- NF-κB — SUCNR1 signaling activates NF-κB pathway via ERK1/2 and AKT; succinate thus triggers inflammatory gene transcription via dual HIF and NF-κB routes
- Vitamin C — PHD enzyme cofactor; high-dose supplementation (>1g/day) enhances HIF-1α degradation by restoring PHD activity in presence of succinate
- Exercise — high-intensity training increases SDH activity and mitochondrial density, improving succinate oxidation capacity and reducing inflammatory accumulation
- Metabolic syndrome — chronic succinate elevation links metabolic dysfunction to immune activation; represents Evolutionary mismatch where metabolic stress mimics hypoxia
- Chronic fatigue syndrome — elevated urinary succinate suggests mitochondrial dysfunction; potential biomarker and therapeutic target
- Sleep apnea — intermittent hypoxia cycles drive repeated succinate accumulation and HIF activation, contributing to cardiovascular complications